Sign in or create an account to add this stock to your watchlist.
About Aimmune Therapeutics (NASDAQ:AIMT)
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. The company has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AIMT
CUSIPN/A
Phone650-614-5220
Debt
Debt-to-Equity RatioN/A
Current Ratio10.86
Quick Ratio10.86
Price-To-Earnings
Trailing P/E Ratio-12.70
Forward P/E Ratio-11.31
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.67 per share
Price / Book5.88
Profitability
EPS (Most Recent Fiscal Year)($2.61)
Net Income$-131,320,000.00
Net MarginsN/A
Return on Equity-64.95%
Return on Assets-58.54%
Miscellaneous
Employees131
Outstanding Shares58,020,000
Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions
What is Aimmune Therapeutics' stock symbol?
Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."
How were Aimmune Therapeutics' earnings last quarter?
Aimmune Therapeutics Inc (NASDAQ:AIMT) posted its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.21. During the same period last year, the firm posted ($0.52) EPS. View Aimmune Therapeutics' Earnings History.
What price target have analysts set for AIMT?
8 brokers have issued twelve-month price objectives for Aimmune Therapeutics' stock. Their predictions range from $30.00 to $80.00. On average, they expect Aimmune Therapeutics' share price to reach $56.1263 in the next twelve months. View Analyst Ratings for Aimmune Therapeutics.
What are Wall Street analysts saying about Aimmune Therapeutics stock?
Here are some recent quotes from research analysts about Aimmune Therapeutics stock:
- 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (5/11/2018)
- 2. Cantor Fitzgerald analysts commented, "A stock now perhaps better suited for investors than traders. In our view, the investment profile for AIMT stock changed significantly once top-line data from the Phase 3 PALISADE trial were released. Aside from the company’s IPO, maybe, the data release constitutes the most important event in the company’s history, we believe. Although AIMT plans to develop other treatments, because peanut allergy is the most prevalent food allergy, the NPV of additional therapies is probably lower than that of AR101. We suspect, too, that the market may discount a higher pTS for other programs now that POC has been established." (5/9/2018)
Who are some of Aimmune Therapeutics' key competitors?
Some companies that are related to Aimmune Therapeutics include SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), FibroGen (FGEN), GW Pharmaceuticals (GWPH) and Ligand Pharmaceuticals (LGND).
Who are Aimmune Therapeutics' key executives?
Aimmune Therapeutics' management team includes the folowing people:
- Dr. Stephen George Dilly, Pres, CEO & Director (Age 58)
- Mr. Jeffrey H. Knapp, Chief Operating Officer (Age 52)
- Dr. Daniel C. Adelman M.D., Chief Medical Officer (Age 61)
- Mr. Eric H. Bjerkholt, CFO & Principal Accounting Officer (Age 58)
- Dr. Laura Hansen Ph.D., VP of Investor Relations
When did Aimmune Therapeutics IPO?
(AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.
Has Aimmune Therapeutics been receiving favorable news coverage?
News stories about AIMT stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aimmune Therapeutics earned a news sentiment score of 0.15 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.05 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Aimmune Therapeutics' major shareholders?
Aimmune Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.31%), Eventide Asset Management LLC (2.70%), Eagle Asset Management Inc. (2.41%), Palo Alto Investors LP (2.34%), Point72 Asset Management L.P. (1.86%) and Carillon Tower Advisers Inc. (1.66%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Foresite Capital Fund Ii, LP, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics.
Which major investors are selling Aimmune Therapeutics stock?
AIMT stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., TLP Group LLC, Point72 Asset Management L.P., Rock Springs Capital Management LP, New York State Common Retirement Fund, Barclays PLC and Citigroup Inc.. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Daniel C Md Adelman, Douglas T Sheehy, Mary M Rozenman, Stephen George Dilly and Susan E Barrowcliffe. View Insider Buying and Selling for Aimmune Therapeutics.
Which major investors are buying Aimmune Therapeutics stock?
AIMT stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Loomis Sayles & Co. L P, Eventide Asset Management LLC, BlackRock Inc., Massachusetts Financial Services Co. MA, Palo Alto Investors LP, Spark Investment Management LLC and Foresite Capital Management III LLC. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Bakker Juliet Tammenoms, Eric Bjerkholt, Kathryn E Falberg and Patrick G Enright. View Insider Buying and Selling for Aimmune Therapeutics.
How do I buy shares of Aimmune Therapeutics?
Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aimmune Therapeutics' stock price today?
One share of AIMT stock can currently be purchased for approximately $33.35.
How big of a company is Aimmune Therapeutics?
Aimmune Therapeutics has a market capitalization of $1.92 billion. The biotechnology company earns $-131,320,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Aimmune Therapeutics employs 131 workers across the globe.
How can I contact Aimmune Therapeutics?
Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]
MarketBeat Community Rating for Aimmune Therapeutics (AIMT)
MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aimmune Therapeutics (NASDAQ:AIMT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Aimmune Therapeutics in the last 12 months. Their average twelve-month price target is $56.1263, suggesting that the stock has a possible upside of 68.29%. The high price target for AIMT is $80.00 and the low price target for AIMT is $30.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $56.1263 | $60.1250 | $56.75 | $53.25 |
| Price Target Upside: | 68.29% upside | 102.24% upside | 77.45% upside | 52.36% upside |
Aimmune Therapeutics (NASDAQ:AIMT) Consensus Price Target History
Aimmune Therapeutics (NASDAQ:AIMT) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Aimmune Therapeutics (NASDAQ:AIMT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aimmune Therapeutics (NASDAQ AIMT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 24.56%
Institutional Ownership Percentage: 81.31%
Aimmune Therapeutics (NASDAQ AIMT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/5/2018 | Douglas T Sheehy | Insider | Sell | 3,523 | $36.52 | $128,659.96 | 32,500 |  |
| 3/1/2018 | Mary M Rozenman | Insider | Sell | 1,807 | $33.10 | $59,811.70 | | |
| 2/26/2018 | Eric Bjerkholt | CFO | Buy | 3,125 | $32.00 | $100,000.00 | | |
| 2/26/2018 | Kathryn E Falberg | Director | Buy | 30,000 | $32.00 | $960,000.00 | | |
| 2/22/2018 | Bakker Juliet Tammenoms | Major Shareholder | Buy | 9,375 | $32.00 | $300,000.00 | 16,651 | |
| 2/22/2018 | Patrick G Enright | Director | Buy | 15,593 | $32.00 | $498,976.00 | 22,869 | |
| 2/5/2018 | Douglas T Sheehy | Insider | Sell | 1,648 | $35.87 | $59,113.76 | | |
| 2/1/2018 | Mary M Rozenman | Insider | Sell | 6,592 | $35.36 | $233,093.12 | | |
| 1/24/2018 | Douglas T Sheehy | Insider | Sell | 1,875 | $38.15 | $71,531.25 | 1,875 | |
| 1/16/2018 | Daniel C Md Adelman | Insider | Sell | 9,933 | $40.00 | $397,320.00 | 26,784 | |
| 1/12/2018 | Daniel C Md Adelman | Insider | Sell | 26,784 | $40.00 | $1,071,360.00 | 26,784 | |
| 1/4/2018 | Douglas T Sheehy | Insider | Sell | 1,648 | $37.33 | $61,519.84 | 1,648 | |
| 1/2/2018 | Susan E Barrowcliffe | Insider | Sell | 75,000 | $37.14 | $2,785,500.00 | | |
| 12/27/2017 | Daniel C Md Adelman | Insider | Sell | 3,283 | $40.00 | $131,320.00 | 3,283 | |
| 12/26/2017 | Douglas T Sheehy | Insider | Sell | 1,875 | $39.44 | $73,950.00 | 1,875 | |
| 12/4/2017 | Douglas T Sheehy | Insider | Sell | 1,906 | $38.66 | $73,685.96 | 1,906 | |
| 11/30/2017 | Douglas T Sheehy | Insider | Sell | 3,750 | $37.00 | $138,750.00 | 3,750 | |
| 11/9/2017 | Douglas T Sheehy | Insider | Sell | 1,905 | $33.00 | $62,865.00 | 1,905 | |
| 10/23/2017 | Douglas T Sheehy | Insider | Sell | 47,425 | $34.44 | $1,633,317.00 | 34,300 | |
| 10/16/2017 | Stephen George Dilly | CEO | Sell | 1,154 | $26.24 | $30,280.96 | | |
| 10/6/2017 | Stephen George Dilly | CEO | Sell | 4,047 | $26.31 | $106,476.57 | | |
| 10/5/2017 | Stephen George Dilly | CEO | Sell | 14,689 | $26.24 | $385,439.36 | | |
| 10/4/2017 | Stephen George Dilly | CEO | Sell | 80,110 | $26.23 | $2,101,285.30 | | |
| 9/25/2017 | Stephen George Dilly | CEO | Sell | 100,000 | $25.01 | $2,501,000.00 | | |
| 9/25/2017 | Susan E Barrowcliffe | Insider | Sell | 20,000 | $25.00 | $500,000.00 | 20,000 | |
| 9/7/2017 | Mary M Rozenman | Insider | Sell | 30,000 | $22.50 | $675,000.00 | 30,129 | |
| 9/6/2017 | Susan E Barrowcliffe | Insider | Sell | 18,390 | $22.00 | $404,580.00 | 3,223 | |
| 7/27/2017 | Susan E Barrowcliffe | Insider | Sell | 500 | $22.00 | $11,000.00 | 500 | |
| 7/26/2017 | Stephen George Dilly | Insider | Sell | 50,000 | $21.46 | $1,073,000.00 | | |
| 7/25/2017 | Susan E Barrowcliffe | Insider | Sell | 6,110 | $22.00 | $134,420.00 | 960 | |
| 7/21/2017 | Douglas T. Sheehy | Insider | Sell | 7,460 | $21.66 | $161,583.60 | | |
| 7/17/2017 | Mary M Rozenman | Insider | Sell | 14,940 | $21.44 | $320,313.60 | 9,103 | |
| 7/5/2017 | Mary M Rozenman | Insider | Sell | 45,060 | $20.85 | $939,501.00 | 30,129 | |
| 7/3/2017 | Susan E Barrowcliffe | Insider | Sell | 15,000 | $20.26 | $303,900.00 | 15,000 | |
| 6/23/2017 | Stephen George Dilly | Insider | Sell | 49,400 | $20.21 | $998,374.00 | | |
| 5/12/2017 | Eric Bjerkholt | CFO | Buy | 5,000 | $19.84 | $99,200.00 | 5,000 | |
| 5/10/2017 | Stephen George Dilly | Insider | Sell | 600 | $20.15 | $12,090.00 | | |
| 4/3/2017 | Warren L Desouza | CFO | Sell | 15,000 | $21.58 | $323,700.00 | 35,681 | |
| 3/21/2017 | Warren L Desouza | CFO | Sell | 10,000 | $22.95 | $229,500.00 | 30,681 | |
| 11/4/2016 | Mary M Rozenman | Insider | Sell | 24,096 | $17.60 | $424,089.60 | 24,096 | |
| 10/5/2016 | Mary M Rozenman | Insider | Sell | 25,000 | $16.80 | $420,000.00 | 25,000 | |
| 9/8/2016 | Mary M Rozenman | Insider | Sell | 30,000 | $16.80 | $504,000.00 | 30,000 | |
| 5/31/2016 | Foresite Capital Fund Ii, L.P. | Major Shareholder | Sell | 240,000 | $15.23 | $3,655,200.00 | | |
| 3/29/2016 | Longitude Capital Partners Ii, | Major Shareholder | Buy | 78,504 | $13.87 | $1,088,850.48 | | |
(Data available from 1/1/2013 forward)
Aimmune Therapeutics (NASDAQ AIMT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Head to Head Analysis: ProQR Therapeutics (PRQR) versus Aimmune Therapeutics (AIMT)
www.americanbankingnews.com - May 22 at 11:08 PM |
 | Aimmune Nearing Critical Point In Valuation
seekingalpha.com - May 20 at 5:44 PM |
| Aimmune Therapeutics (AIMT) Now Covered by Piper Jaffray
www.americanbankingnews.com - May 18 at 5:15 PM |
 | Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical ...
www.businesswire.com - May 16 at 8:40 AM |
| Aimmune Therapeutics (AIMT) Expected to Announce Earnings of -$0.70 Per Share
www.americanbankingnews.com - May 15 at 10:11 AM |
 | Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
finance.yahoo.com - May 15 at 8:47 AM |
| Wedbush Comments on Aimmune Therapeutics' Q1 2019 Earnings (AIMT)
www.americanbankingnews.com - May 14 at 4:27 AM |
| Zacks Investment Research Downgrades Aimmune Therapeutics (AIMT) to Hold
www.americanbankingnews.com - May 11 at 5:43 PM |
| Aimmune Therapeutics (AIMT) Given a $47.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - May 11 at 3:57 PM |
| Aimmune Therapeutics Target of Unusually High Options Trading (AIMT)
www.americanbankingnews.com - May 11 at 2:20 AM |
| Aimmune Therapeutics (AIMT) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 11 at 1:28 AM |
| Aimmune Therapeutics (AIMT) Earns Outperform Rating from Wedbush
www.americanbankingnews.com - May 10 at 1:28 PM |
| Aimmune Therapeutics (AIMT) Posts Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 3:16 PM |
| Cantor Fitzgerald Reiterates Buy Rating for Aimmune Therapeutics (AIMT)
www.americanbankingnews.com - May 9 at 3:12 PM |
| Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June
finance.yahoo.com - May 9 at 8:33 AM |
| Aimmune Therapeutics Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 5:24 PM |
| Aimmune Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:24 PM |
| Aimmune Therapeutics (AIMT) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - May 5 at 2:45 AM |
| -$0.66 EPS Expected for Aimmune Therapeutics (AIMT) This Quarter
www.americanbankingnews.com - April 27 at 7:20 PM |
| Aimmune Therapeutics Sees Unusually Large Options Volume (AIMT)
www.americanbankingnews.com - April 27 at 7:44 AM |
| Backing Blackstone For A Decade - Cramer's Lightning Round (4/23/18)
seekingalpha.com - April 24 at 8:30 AM |
| Global Peanut Allergy Therapeutics - 2018 Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations ...
www.businesswire.com - April 21 at 8:31 AM |
 | Market Trends Toward New Normal in Genuine Parts, Energizer, Arthur J ...
globenewswire.com - April 20 at 5:11 PM |
| Market Trends Toward New Normal in Genuine Parts, Energizer, Arthur J. Gallagher, Aimmune Therapeutics, Roku, and Premier — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - April 19 at 8:30 AM |
| Aimmune Therapeutics (AIMT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 16 at 1:44 AM |
| Brokerages Expect Aimmune Therapeutics (AIMT) Will Announce Earnings of -$0.66 Per Share
www.americanbankingnews.com - April 10 at 9:13 PM |
| Aimmune Therapeutics (AIMT) Given Outperform Rating at Wedbush
www.americanbankingnews.com - April 6 at 11:11 AM |
| Aimmune Therapeutics (AIMT) PT Set at $62.00 by Piper Jaffray
www.americanbankingnews.com - April 5 at 12:03 PM |
| Aimmune Therapeutics (AIMT) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 8:10 PM |
| Is This Why AnaptysBio Inc. Fell on Monday?
finance.yahoo.com - April 3 at 8:39 AM |
| Aimmune Therapeutics (AIMT) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 30 at 6:16 PM |
| Credit Suisse Group Analysts Give Aimmune Therapeutics (AIMT) a $45.00 Price Target
www.americanbankingnews.com - March 28 at 7:04 PM |
| Protecting children from severe peanut allergies
finance.yahoo.com - March 27 at 5:03 PM |
| U.S. Biotech/Pharma Sector Daily Observations Letter: March 26, 2018
seekingalpha.com - March 27 at 8:44 AM |
| After-hours buzz: RHT, ANAB & more
finance.yahoo.com - March 27 at 8:44 AM |
| Aimmune Therapeutics (AIMT) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - March 26 at 3:13 PM |
| Aimmune Therapeutics (AIMT) Now Covered by Royal Bank of Canada
www.americanbankingnews.com - March 25 at 8:16 AM |
| Credit Suisse Group Reiterates "$45.00" Price Target for Aimmune Therapeutics (AIMT)
www.americanbankingnews.com - March 24 at 8:55 PM |
| Aimmune Therapeutics Inc (AIMT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 22 at 1:36 AM |
| Wedbush Research Analysts Lift Earnings Estimates for Aimmune Therapeutics Inc (AIMT)
www.americanbankingnews.com - March 19 at 2:14 AM |
 | AIMMUNE THERAPEUTICS, INC. - StreetInsider.com
www.streetinsider.com - March 13 at 8:41 AM |
| Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results - Business Wire (press release)
www.businesswire.com - March 13 at 8:41 AM |
| Aimmune Therapeutics Inc (AIMT) Short Interest Up 49.0% in February
www.americanbankingnews.com - March 13 at 1:53 AM |
| Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 12 at 11:01 AM |
| Zacks: Brokerages Expect Aimmune Therapeutics Inc (AIMT) Will Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - March 7 at 3:18 PM |
| Aimmune Therapeutics to Participate in Four Investor Conferences in March - Business Wire (press release)
www.businesswire.com - March 7 at 8:38 AM |
| Aimmune Therapeutics to Participate in Four Investor Conferences in March
finance.yahoo.com - March 7 at 8:38 AM |
| Cantor Fitzgerald Analysts Lower Earnings Estimates for Aimmune Therapeutics Inc (AIMT)
www.americanbankingnews.com - March 7 at 7:26 AM |
| Douglas T. Sheehy Sells 3,523 Shares of Aimmune Therapeutics Inc (AIMT) Stock
www.americanbankingnews.com - March 6 at 9:44 PM |
| Aimmune Therapeutics (AIMT) Receives "Outperform" Rating from Wedbush
www.americanbankingnews.com - March 6 at 2:17 PM |
Aimmune Therapeutics (NASDAQ:AIMT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aimmune Therapeutics (NASDAQ:AIMT) Income Statement, Balance Sheet and Cash Flow Statement
Aimmune Therapeutics (NASDAQ AIMT) Stock Chart for Thursday, May, 24, 2018
Loading chart…
